SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma Advanced Research falls on reporting net loss of Rs 61 crore in Q1

27 Jul 2021 Evaluate

Sun Pharma Advanced Research Company is currently trading at Rs. 243.40, down by 17.60 points or 6.74% from its previous closing of Rs. 261.00 on the BSE.

The scrip opened at Rs. 251.80 and has touched a high and low of Rs. 256.55 and Rs. 239.40 respectively. So far 252632 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 271.95 on 26-Jul-2021 and a 52 week low of Rs. 141.00 on 31-Mar-2021.

Last one week high and low of the scrip stood at Rs. 271.95 and Rs. 239.40 respectively. The current market cap of the company is Rs. 6420.16 crore.

The promoters holding in the company stood at 68.46%, while Institutions and Non-Institutions held 2.63% and 28.91% respectively.

Sun Pharma Advanced Research (SPARC) has reported net loss at Rs 61.37 crore for the quarter  ended June 30, 2021 as compared to net profit of Rs 56.69 crore for the same quarter in the previous year. Total income of the company decreased by 87.75% at Rs 22.79 crore for Q1FY22 as compared Rs 186.11 crore for the corresponding quarter previous year.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

147.90 -4.25 (-2.79%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 435.70
Indegene 486.80
CMS Info Systems 318.00
JITF Infralogistics 338.00
Sagility 42.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×